These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 12437480)
21. Use of whole-genome association scans in disease gene identification, drug discovery and development. Roses AD; St Jean PL; Ehm MG IDrugs; 2007 Nov; 10(11):797-804. PubMed ID: 17968762 [TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics: historical perspective and current status. Charlab R; Zhang L Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846 [TBL] [Abstract][Full Text] [Related]
23. Methodological and statistical issues in pharmacogenomics. Peters BJ; Rodin AS; de Boer A; Maitland-van der Zee AH J Pharm Pharmacol; 2010 Feb; 62(2):161-6. PubMed ID: 20487194 [TBL] [Abstract][Full Text] [Related]
25. Pharmacogenomics of cancer chemotherapy-induced toxicity. Miller CR; McLeod HL J Support Oncol; 2007 Jan; 5(1):9-14. PubMed ID: 17265780 [TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics - therapeutic and ethical issues. Patowary S Kathmandu Univ Med J (KUMJ); 2005; 3(4):428-30. PubMed ID: 16449851 [TBL] [Abstract][Full Text] [Related]
27. Current pharmacogenomic approaches to clinical drug development. Murphy MP Pharmacogenomics; 2000 May; 1(2):115-23. PubMed ID: 11256585 [TBL] [Abstract][Full Text] [Related]
28. Assessing patient readiness for the clinical adoption of personalized medicine. Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419 [TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen. Vandenbroeck K; Matute C Pharmacogenomics; 2008 May; 9(5):639-45. PubMed ID: 18466107 [TBL] [Abstract][Full Text] [Related]
33. Theoretical basis for the identification of allelic variants that encode drug efficacy and toxicity. Lin M; Wu R Genetics; 2005 Jun; 170(2):919-28. PubMed ID: 15802521 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacogenomics: the quest for individualized therapy]. López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270 [TBL] [Abstract][Full Text] [Related]
35. Methods for analysis in pharmacogenomics: lessons from the Pharmacogenetics Research Network Analysis Group. Srinivasan BS; Chen J; Cheng C; Conti D; Duan S; Fridley BL; Gu X; Haines JL; Jorgenson E; Kraja A; Lasky-Su J; Li L; Rodin A; Wang D; Province M; Ritchie MD Pharmacogenomics; 2009 Feb; 10(2):243-51. PubMed ID: 19207025 [TBL] [Abstract][Full Text] [Related]
36. 4th Annual Pharmacogenomics and Medicine Lectures. Oestreicher P Pharmacogenomics; 2001 Aug; 2(3):291-6. PubMed ID: 11939134 [TBL] [Abstract][Full Text] [Related]
38. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Cacabelos R Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277 [TBL] [Abstract][Full Text] [Related]
39. Translating pharmacogenomics: challenges on the road to the clinic. Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640 [TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics and pharmacogenomics in the discovery and development of medicines. Roses AD Novartis Found Symp; 2000; 229():63-6; discussion 66-70. PubMed ID: 11084930 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]